| __timestamp | BioCryst Pharmaceuticals, Inc. | Cytokinetics, Incorporated |
|---|---|---|
| Wednesday, January 1, 2014 | 122000 | 44426000 |
| Thursday, January 1, 2015 | 1896000 | 46398000 |
| Friday, January 1, 2016 | 2699000 | 59897000 |
| Sunday, January 1, 2017 | 1702000 | 90296000 |
| Monday, January 1, 2018 | 471000 | 89135000 |
| Tuesday, January 1, 2019 | 4101000 | 86125000 |
| Wednesday, January 1, 2020 | 1676000 | 96951000 |
| Friday, January 1, 2021 | 7264000 | 159938000 |
| Saturday, January 1, 2022 | 6594000 | 240813000 |
| Sunday, January 1, 2023 | 4661000 | 330123000 |
Data in motion
In the dynamic world of biotechnology, cost efficiency is a critical factor for success. Over the past decade, Cytokinetics, Incorporated and BioCryst Pharmaceuticals, Inc. have demonstrated contrasting approaches to managing their cost of revenue. From 2014 to 2023, Cytokinetics consistently reported higher costs, peaking at approximately $330 million in 2023, a staggering 2,600% increase from 2014. In contrast, BioCryst's cost of revenue remained relatively stable, with a modest peak of around $7 million in 2021. This disparity highlights Cytokinetics' aggressive investment in research and development, potentially positioning them for groundbreaking advancements. Meanwhile, BioCryst's steady approach may reflect a focus on optimizing existing processes. As the biotech landscape evolves, these strategies offer valuable insights into how companies balance innovation with financial prudence.
Cost Insights: Breaking Down Johnson & Johnson and Cytokinetics, Incorporated's Expenses
Cost of Revenue Trends: Pfizer Inc. vs BioCryst Pharmaceuticals, Inc.
Neurocrine Biosciences, Inc. vs BioCryst Pharmaceuticals, Inc.: Efficiency in Cost of Revenue Explored
Cost of Revenue Trends: Dr. Reddy's Laboratories Limited vs BioCryst Pharmaceuticals, Inc.
Analyzing Cost of Revenue: Bio-Techne Corporation and BioCryst Pharmaceuticals, Inc.
Cost Insights: Breaking Down Catalent, Inc. and BioCryst Pharmaceuticals, Inc.'s Expenses
Comparing Cost of Revenue Efficiency: Pharming Group N.V. vs BioCryst Pharmaceuticals, Inc.
Cost Insights: Breaking Down Cytokinetics, Incorporated and Xenon Pharmaceuticals Inc.'s Expenses
Analyzing Cost of Revenue: Cytokinetics, Incorporated and Mesoblast Limited
Cost of Revenue Trends: Cytokinetics, Incorporated vs Xencor, Inc.
Cost Management Insights: SG&A Expenses for Cytokinetics, Incorporated and BioCryst Pharmaceuticals, Inc.
Cost of Revenue: Key Insights for MorphoSys AG and BioCryst Pharmaceuticals, Inc.